Latigo is a clinical-stage biopharmaceutical company developing non-opioid pain medicines. The company focuses on inhibiting Nav1.8, a voltage-gated sodium channel in peripheral nerve tissue that transmits pain signals. By blocking these peripheral nerves rather than the brain, Latigo aims to provide pain relief without the addiction risk of opioids. Latigo develops its lead candidate, LTG-001, as an oral treatment for moderate-to-severe acute pain. The company completed a Phase 3-quality trial for LTG-001 and plans to start a Phase 3 bunionectomy trial in H2 2026. Latigo also develops LTG-321, a high-potency inhibitor for once-daily dosing in chronic musculoskeletal pain, which is currently in a Phase 2 trial for osteoarthritis. Latigo designed its third candidate, LTG-418, for lower dosing and potential non-oral delivery formats like gels or patches. Latigo is pre-revenue and funds operations through capital raises. If its candidates receive regulatory approval, Latigo intends to commercialize them directly by targeting orthopedic surgeons and pain specialists. Latigo argues its lead candidate offers faster onset and fewer drug-drug interaction risks than the first approved Nav1.8 inhibitor. The company’s strategy involves advancing its pipeline toward regulatory submissions and building a franchise for both acute and chronic pain. Latigo maintains global rights to its pipeline but may explore international partnerships.